对《β-内酰胺酶抑制剂的最佳药代动力学/药效学靶点是什么？一项系统评价》的评论 - Suppr | 超能文献

Comment on: 'What are the optimal pharmacokinetic/pharmacodynamic targets for beta-lactamase inhibitors? A systematic review'.

作者信息

Bentley Darren J

机构信息

Certara Drug Development Solutions, Certara UK, Level 2-Acero, 1 Concourse Way, Sheffield S1 2BJ, UK.

出版信息

J Antimicrob Chemother. 2024 Aug 1;79(8):2081-2082. doi: 10.1093/jac/dkae202.

DOI:10.1093/jac/dkae202

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Comment on: 'What are the optimal pharmacokinetic/pharmacodynamic targets for beta-lactamase inhibitors? A systematic review'.对《β-内酰胺酶抑制剂的最佳药代动力学/药效学靶点是什么？一项系统评价》的评论

J Antimicrob Chemother. 2024 Aug 1;79(8):2081-2082. doi: 10.1093/jac/dkae202.

2

What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.β-内酰胺酶抑制剂的最佳药代动力学/药效学目标是什么？系统评价。

J Antimicrob Chemother. 2024 May 2;79(5):946-958. doi: 10.1093/jac/dkae058.

3

Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.β-内酰胺酶抑制剂的药代动力学和药效学。

Pharmacotherapy. 2019 Feb;39(2):182-195. doi: 10.1002/phar.2210. Epub 2019 Jan 20.

4

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.他唑巴坦与哌拉西林联合用药在体外感染模型中的药代动力学-药效学研究

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

5

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.CB-618 联合头孢吡肟、头孢他啶、头孢他唑巴坦或美罗培南的药代动力学-药效学：一种独立的β-内酰胺酶抑制剂的药理学基础。

Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.00630-17. Print 2017 Dec.

6

A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.一种新型基于机制的药代动力学-药效学（PKPD）模型，用于描述头孢他啶/阿维巴坦对产β-内酰胺酶的革兰氏阴性菌的疗效。

J Antimicrob Chemother. 2020 Feb 1;75(2):400-408. doi: 10.1093/jac/dkz440.

7

The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.在感染体外模型中研究了阿维巴坦与头孢洛林或头孢他啶联合使用对产β-内酰胺酶肠杆菌科细菌的药效学。

J Antimicrob Chemother. 2017 Mar 1;72(3):762-769. doi: 10.1093/jac/dkw480.

8

NOTA: a potent metallo-β-lactamase inhibitor.注意：一种强效金属β-内酰胺酶抑制剂。

J Antimicrob Chemother. 2015 May;70(5):1594-6. doi: 10.1093/jac/dku538. Epub 2015 Jan 6.

9

Ebselen as a potent covalent inhibitor of New Delhi metallo-β-lactamase (NDM-1).依布硒啉作为新型德里金属β-内酰胺酶（NDM-1）的强效共价抑制剂。

Chem Commun (Camb). 2015 Jun 11;51(46):9543-6. doi: 10.1039/c5cc02594j.

10

Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.阿维巴坦对在同基因大肠杆菌菌株中表达的选定β-内酰胺酶的抑制活性。

Diagn Microbiol Infect Dis. 2016 Sep;86(1):83-5. doi: 10.1016/j.diagmicrobio.2016.03.002. Epub 2016 Mar 2.

引用本文的文献

1

A model-based evaluation of the pharmacokinetics-pharmacodynamics (PKPD) of avibactam in combination with ceftazidime.基于模型的阿维巴坦与头孢他啶联合用药的药代动力学-药效学（PKPD）评价。

JAC Antimicrob Resist. 2025 Mar 11;7(2):dlaf036. doi: 10.1093/jacamr/dlaf036. eCollection 2025 Apr.

2

A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly.哌拉西林/他唑巴坦在不同患者群体中的汇总药代动力学分析：从早产儿到老年人。

Clin Pharmacokinet. 2025 Jan;64(1):107-126. doi: 10.1007/s40262-024-01460-6. Epub 2024 Dec 25.